CompletedPhase 2

Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

United States39 participantsStarted 2015-04-23

Plain-language summary

Background: \- PIK3CA-related overgrowth spectrum (PROS) is caused by changes in the PIK3CA gene. This gene makes a protein that communicates with other proteins in the body to cause cells to grow. Alterations in PIK3CA change the chemical signals in the body and cause overgrowth in fatty, vascular and other tissues. Sirolimus is a drug that reduces the signals sent by one of the proteins in this chemical signaling pathway. Researchers want to learn whether the drug sirolimus can reduce or stabilize some of the overgrowth that patients with PROS experience. Objectives: \- To measure how the overgrowth of patients with PROS changes over time and whether taking a drug called sirolimus can reduce or stabilize a person s overgrowth. Eligibility: \- People ages 3 to 65 years old with a confirmed mutation or alteration of the PIK3CA gene in the person s affected tissues (a somatic mutation). Design: * Participants will be screened with medical history and genetic counseling. * First 6 months: Participants will have their overgrowth monitored. * Next 6 months: Participants will take sirolimus once or twice a day. * Participants will have to visit the clinic several times, and stay in the area for 4 to 5 days each time. * Participants will have a one month-long visit to the clinic. * During clinic visits, participants will have: * Blood and urine tests. * Photographs of their physical features. * Scans, including an MRI and DEXA, and possibly x-rays and CT scans. * For the MRI and CT scans, participants will lie in a machine that takes pictures of their body. * The DEXA involves a small amount of radiation. * They may have: * Non-invasive heart function tests. * Lung function tests. * Participants will have several blood and urine tests between visits. * Participants will complete surveys and keep a diary of their treatment and side effects. * Participants may visit other health specialists or undergo other tests based on side effects. * One month after stopping the study drug, participants will have 1 clinic visit.

Who can participate

Age range3 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* INCLUSION CRITERIA: * Age: greater than or equal to 3 years to less than or equal to 65 years * Male or Female * Confirmed PIK3CA somatic mutation * Measurably progressive overgrowth, in current progression or with clinical history of overgrowth progression * Adequate Bone Marrow Function Defined as: * Peripheral absolute neutrophil count (ANC) greater than or equal to 1500/microliter, except for those participants with an absolute neutrophil count (ANC) of 1000-1500, caused by a benign condition associated with moderately decreased neutrophils known as Benign Ethnic Neutropenia (BEN), d those who have an ANC of 1000-1500 caused by a confirmed infection, which resolves with treatment of infection to greater than or equal to 1500. * Platelet count less than or equal to 100,000/microliter * Hemoglobin less than or equal to 10.0 gm/dL * Adequate Renal Function Defined as: * A serum creatinine based on age as follows: * Age (years) \[Maximum Serum Creatinine (mg/dl)\] * Less than or equal to 5 \[0.8 mg/dl\] * 5 less than age less than or equal to10 \[1.0 mg/dl\] * 10 less than age less than or equal to 15 \[1.2 mg/dl\] * Less than 15 \[1.5 mg/dl\] * OR a creatinine clearance or radioisotope GFR greater than or equal to 70ml/min/1.73 m2 * Adequate Liver Function Defined As: * Bilirubin (sum of conjugated + unconjugated) less than or equal to 1.5 x upper limit of normal (ULN) for age, and * SGPT (ALT) less than or equal to 5 x upper limit of normal (…

What they're measuring

Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA

Timeframe: Run-in (0-26 weeks), treatment (26-52 weeks)

Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by MRI Scan

Timeframe: Run-in (0-26 weeks), treatment (26-52 weeks)

Trial details

NCT IDNCT02428296

SponsorNational Human Genome Research Institute (NHGRI)

Sponsor typeNIH

Study typeINTERVENTIONAL

Primary completion2018-02-14

Results submitted2019-11-14